Tests combined diabetes drug strategies to lower blood sugar in type 2 diabetes
Tests combined drug and glucose monitor strategies in adults with type 2 diabetes.
Key facts
- Who runs it
- Kyu Chang Won
- Where
- Daegu and Seoul, South KoreaSee the 2 sites
- Trial code
- Registry title
- A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
- Status
- Recruiting
- People taking part
- 5,950 people, planned
- Started
- 21 Nov 2024
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dual-combination therapy
- Triple-combination therapy
- Dexcom G7, Pasta
- Record updated
- 24 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who still have raised HbA1c on diabetes tablets and who also have heart or blood vessel risk factors or diabetes complications.
- Age
- 19 years and older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes with HbA1c 7.0% (53 mmol/mol) or higher and under 10.0% (86 mmol/mol) on one, two or three diabetes tablets. Also needs heart disease, stroke, long diabetes (10 years or more), kidney, eye or nerve problems, or two or more heart risk factors.
- Earlier treatment
- Must already take diabetes tablets (one, two or three drugs, at a submaximal dose for three).
- Biomarker or test result
- HbA1c 7.0% (53 mmol/mol) or higher and under 10.0% (86 mmol/mol)
Main reasons for not taking part
- Type 1 diabetes
- Kidney function (eGFR) under 45 ml/min/1.73m²
- Liver tests (AST or ALT) more than 3 times the upper normal limit
- Heart failure with symptoms (NYHA Class III or IV)
- Hospital stay for a heart or blood vessel event in the last 3 months
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- ≥19 years of age
- Patient agreed to participate in the study and signed a written informed consent form
- Type 2 diabetes (ADA criteria)
- HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was administered) with oral antidiabetic drugs (OADs)
- Any of the following:
- Patients who one or more of the following conditions
- Coronary artery disease
- Atherosclerotic ischemic stroke, transient ischemic attack, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm
- Prevalence of diabetes ≥10 years
- Left ventricular hypertrophy
- Albuminuria
- Chronic kidney disease (eGFR\<60mL/min/1.73m²)
- Diabetic Retinopathy
- Diabetic neuropathy or B. Patients who have two or more of the following cardiovascular risk factors; (1) Family history of early-onset ASCVD (first-degree relatives with disease before age 55 for men and before age 65 for women) (2) Hypertension (on medication or with SBP≥140 mm Hg or DBP≥90 mm Hg) (3) Low HDL cholesterol concentration (\<40 mg/dL) (4) Current smoker (5) Obese (BMI≥25 kg/m²)
Who cannot take part
- History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent
- Contraindications for each assigned drug, as applicable
- Type 1 diabetes
- Symptomatic heart failure (NYHA Class III or IV)
- Currently in active treatment for malignancy
- Estimated GFR\<45 ml/min/1.73m²
- AST or ALT greater than 3 times the normal upper limit
- Pregnant and nursing women
- If the investigator determines that assignment to the standard glycemic control arm raises ethical concerns
Where in South Korea
- Yeungnam University Medical CenterDaegu, South KoreaContact: Won, M.D., Ph.D.Not yet recruiting
- Korea University Anam HospitalSeoul, South KoreaContact: Sin Gon Kim, M.D., Ph.D.Taking people
About the trial
What the trial wants to find out
Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with development of newer antidiabetic drugs which minimize possible harms of intensive glycemic control as well as reduce cardiorenal risks enabled safer glycemic reduction. Thus, this randomized trial aims to evaluate the effects of near normalization of HbA1c with novel approaches on microvascular complications and cardiovascular outcomes in people with T2D.
The 2 groups in the trial
- Standard treatment arm (HbA1c 7.0% target)Existing treatment, for comparison
Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Treatment and Follow-up : Maximum 4 years
Treatment: Dual-combination therapy
- Intensive treatment arm (HbA1c 6.0% target): plus real-time CGMTreatment being tested
Randomly assigned into 2 sub-groups Device: Dexcom G7 plus Kakaohealthcare Pasta. (Barozen Fit is also available.) Treatment and Follow-up : Maximum 4 years
Treatment: Triple-combination therapy and Dexcom G7, Pasta
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Registry Based Randomized Controlled Trial of Multiple Combination Strategies of Intensive Glycemic Control to Reduce a Composite of Macrovascular and Microvascular Events in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH Study)
- Plain-language title
- Tests combined diabetes drug strategies to lower blood sugar in type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 24 April 2025